You're about to create your best presentation ever

Background For Biotech Presentation

Create your presentation by reusing one of our great community templates.

BioTech presentation

Transcript: Difference-gel electrophoresis is.... Confirmation of protein regulation by Western blotting For this study, we used a 2D-DIGE approach to identify proteins associated in natural resistance mechanisms to sulfadiazine (Supplemental data 2). Protein abundance was compared between sulfadiazine sensitive and resistant strains from T. gondii with same genotype. Introduction Identification of differentially expressed proteins in sulfadiazine resistant and sensitive strains of Toxoplasma gondii using difference-gel electrophoresis (DIGE) Discussion and Conclusion. Seven strains of T. gondii tachyzoites were used in this study: RH and ENT (Type I, sensitive strain), TgA 103001 (Type I, resistant strain), ME-49 and PRU (Type II, sensitive strain), TgH 32006 (Type II, resistant strain) and TgH 32045 (defined as Type II variant, resistant strain). Identification of differentially expressed proteins. Sydney Smith In conclusion, we have identified 31 proteins which are differentially modulated between sulfadiazine resistant and sensitive strains of T. gondii according to their genotype. These proteins were predicted to be involved in several different mechanisms such as carbohydrate metabolism, host cell interaction and protein translation. Although none of them allow us to identify directly resistance mechanisms to sulfadiazine at this stage, several of these proteins represent encouraging potential targets to be followed-up. We confirmed by Western blotting proteins regulation of several proteins identified in DIGE: ENO2, IMC1, ROP2, MIC2 and GRA7 in the different strains studied. We also analyzed these proteins regulation in two others sensitive strains of genotype I (ENT) and genotype II (PRU) Ajioka, J.W., Soldati, D., 2007. Toxoplasma Molecular and Cellular Biology. Horizon Biosciences, Norfolk. Ajzenberg, D., Bañuls, A.L., Su, C., Dumètre, A., Demar, M., Carme, B., Dardé, M.L., 2004. Genetic diversity, clonality and sexuality in Toxoplasma gondii. Int. J. Parasitol. 34 (10), 1185–1196. Ajzenberg, D., Collinet, F., Mercier, A., Vignoles, P., Dardé, M.L., 2010. Genotyping of Toxoplasma gondii isolates with 15 microsatellite markers in a single multiplex PCR assay. J. Clin. Microbiol. 48 (12), 4641–4645. Alban, A., David, S.O., Bjorkesten, L., Andersson, C., Sloge, E., Lewis, S., Currie, I., 2003. A novel experimental design for comparative two-dimensional gel analysis: two-dimensional difference gel electrophoresis incorporating a pooled internal standard. Proteomics 3, 36–44. Andrade, H.M., Murta, S.M., Chapeaurouge, A., Perales, J., Nirdé, P., Romanha, A.J., 2008. Proteomic analysis of Trypanosoma cruzi resistance to Benznidazole. J. Proteome Res. 7 (6), 2357–2367. Baatz, H., Mirshahi, A., Puchta, J., Gumbel, H., Hattenbach, L.O., 2006. Reactivation of Toxoplasma retinochoroiditis under atovaquone therapy in an immunocompetent patient. Ocul. Immunol. Inflamm. 14, 185–187. Bohne, W., Gross, U., Ferguson, D.J., Heesemann, J., 1995. Cloning and characterization of a bradyzoite-specifically expressed gene (hsp30/bag1) of Toxoplasma gondii, related to genes encoding small heat-shock proteins of plants. Mol. Microbiol. 16 (6), 1221–1230. Methods and Materials Toxoplasma gondii, the causative agent of toxoplasmosis, is an obligate intracellular protozoan parasite that infects more than one-third of the world’s human population. The population structure of T. gondii consists of three main clonal lineages (Types I, II and III) correlated with virulence expression in mice. Recently, a study reveal a biphasic pattern consisting of regions in the Northern Hemisphere where a few, highly clonal and abundant lineages predominate; elsewhere, and especially in portions of South America are characterized by a diverse assemblage of less common genotypes that show greater evidence of recombination. Results. What is Toxoplasma gondii? a. protozoan parasite b. bed bug c. a protein a. 2G DIGE b. DIGE c. analyzed gel In total, 31 proteins, including four hypothetical proteins, were identified from the three experiments, 44% were overexpressed in resistant strains and 56% were over-expressed in sensitive strains. Interestingly, GRA7 was identified in two gel spots and showed contradictory expression changes in these gel spots: one appearing more abundant in TgH 32045 and the other one in ME-49 There was a variety of methods used; cell structure, Preparation of tachyzoites, DIGE, Sypro Ruby staining, Image analysis and statistics, In-gel tryptic digestion and Western blot analysis Quiz Time!!!! References. How many different strains of T. gondii tachyzoites were used in this study? a. 31 b. 7 c. 1,000,000 There is increasing evidence for the emergence of strains of T. gondii that are resistant to treatment with sulfonamide and/or pyrimethamine-based compounds. In collaboration with Meneceur et al. (2008), we have recently isolated three strains of T. gondii resistant to sulfadiazine. As there is no apparent correlation with strain

Biotech Presentation

Transcript: Jeffreys Big Discovery Jeffreys put together all of the research he had and figured out a way to put the information together The information included a group of messy genetic material that didnt give a clear conclusion https://web.mit.edu/iment/iou/jeffreys.html http://genome.welcome.ac.uk/doc.wtd020877.html http://www.thebrightesthub.com Jeffreys observations led to the last step of his research projects This project was created to look deeper and closely into the different inherited types of genes After coming up with a complicated plan on how to do his research, Jeffreys noticed a new type of DNA formation Jeffreys Shocking Dicovery Jeffreys Research In England Jeffreys learned how to detect single copies if human genes Makes the first observations of introns (non-coding sections of DNA that split up genes) Citations Sir Alec Jeffreys Jeffreys Conclusion Research In Leicester Famous British geneticist Went to Leicester,England to work on his own research in 1997 DNA Fingerprinting Jeffreys' research lead to another discovery. He found out that RFLP's (Restriction Fragment Length Polymorphism), which are segments of DNA that make changes he generic group, were proof of variation in inherited DNA levels After discovering what the RFLP's do, he then pointed out that some DNA segements couldnt inform you about the different types of inherited genes Sir Alec Jeffreys began to see patterns in the genetic formation, he noticed that the DNA this group contained, was the information of a single individual Jeffreys made a conclusion on September 1984, that the projects had led to the discovery of the very first DNA fingerprints ever created

Biotech Presentation

Transcript: Biotechnology Design Team 2007-2 5 3 1 What is Cancer? Cancer: uncontrollably dividing cells that form a tumor This is the most common way to remove tumors where surgeons manually remove the tumor along with some nearby tissue. The Issue: Re-operation 2 Cancer Surgery Surrounding Tissue Surrounding Tissue The surgeon cuts out some surrounding tissue to make sure all possible “hidden” cancer cells have been removed It's hard for surgeons to tell how much surrounding tissue is cancerous during surgery. Post-operative biopsy No left over cancer cells: no re-operation Left over cancer cells: needs re-operation Impacts of the Issue Although re-operation is very common, it is a problematic procedure with far-reaching impacts. Explanation of Impacts Considerations of Re-operation Risk of complications after surgery Psychological and emotional effects Financially Overburdening Increased mortality rate Delayed recovery and treatment Impacts of Re-operation Excessive bleeding, blood clots, or infections in other parts of body $31,000 Average American's salary $150,000 Average cost of cancer treatment May increase anxiety and inflict emotional trauma on patient and family This data was found in a study conducted by the BMJ Journal of Ethics. Mortality rates increase by 27% - 28% Increases the patient's recovery time and delays treatment Risks of no re-operation Risks of Not Re-operating Percent of accurate biopsies 57% 43% "False Negative" - biopsy shows no cancer, but there actually is Percent of Inaccurate biopsies - this means cancer is left undetected and advances to even more dangerous stages. 4 The Solution: iKnife Step 1 1 Electricity heats up the tip of the iKnife 2 Step 2 The hot blade causes cells in the tissue to explode, releasing particles in smoke 3 Step 3 Particles are sucked into a tube, heated, ionized 4 Step 4 The particles in the tube are then fed into a mass spectrometer (which is like an extremely accurate weighing scale) 5 Step 5 A detector on the mass spectrometer outputs this data, which lets surgeons distinguish between cancerous and non-cancerous tissues during the surgery. Overall accuracy of iKnife is Success of iKnife 97.8 % Real Life Scenario Real-Life Scenarios Ben Normal surgery More hidden cancerous tissue left Needed re-operation. Jake False negative Later found that cancer had spread More complicated re-operation was needed Clara Surgery with iKnife All cancerous tissue was removed No re-operation was required

Biotech Presentation

Transcript: Who owns the Patent on Your Genetic Code? Yes No Only If... type something Employers? The Military? They could us it discover cures or treatments for fatal or epidemic diseases that can't be treated today. They could use your code to do testing that you are not comfortable with or you think is wrong, like cloning. If it helps you land your dream job. If it helps them save your life during combat. They discovered that your genes can help cure or threat a disease. Medical Authorities? That kind of information shouldn't matter to a potential partner for life. They could use it to find diseases early and either cure them or help you find a treatment option. If there is a great breakthrough on the therapy or cure of something, and they needed you code to help other people. They could see if you are a carrier of some disease that your child could get and be prepare for it That kind of information might be too private for them to know, and they don't really need it. They could find ways to make you immune to diseases that you could be exposed while deployed over seas Prospectec Spouses? If that helps them decide if you are a good choice of partner. That way you can pay for future treatments if you have a disease that takes years to show and that is uncurable You have the risk of someone breaking into the system and stealing your information and use it for who knows what Scientists? They could use you as a tests subject without you knowing, because you are their property To ensure that you are the best suitable employee for the job they require. If you wanted to be ensure for a disease that takes a long time to show and to take any effect on you. Insurance Companies? They could be doing experiment that are controversial and could use your code in them.

Biotech Presentation

Transcript: C Q&A Frontier Issues & UNFPA T - Benefits of Frontier Tech Overview - Biotech one example - Why should we care about frontier tech? Frontier Technology - CRISPR-Cas9 - In Vitro Fertilization - The combinative value The Technology: The Technology 1 - Revolutionized genetic therapy. - Gene manipulation i.e. "Designer Babies". - Curing previously incurable diseases. For us that means HIV. - Reduce total number of maternal deaths are attributed to HIV. CRISPR-Cas9 2 - Tech isn't cutting edge, its uses are. - Preimplantation Genetic Screening/Diagnosing (PGS/PGD). - Goodbye unwanted inherited traits! No more sickle cell, Huntington's, double X chromosones, hemophilia, etc...wait a minute. - 117 million women missing from Eastern Europe and Asia, with certain areas seeing up to 25% more male births than female. Any country with less regulation of sex selection pose serious threat for female population...or maybe not? In Vitro Fertilization 3 - Current CRISPR-Cas9 treatments cost ~$375,000. - Possible to apply CRISPR treatments via in vitro to reduce price. $20,000-40,000 The Synergy - Germline modification = exponential proliferation of resistant gene. - A couple generations later inoculated population. Business Model How This Fits Additional Benefits/Concerns Global Concerns - Global scale implications of this technology. Unregulated, ungoverned, ethically ambiguous. To name a few... - Pricing = unviable for low-income countries/persons. (SDG 10.3) - 10/90 gap. - Safety is a major concern. The Bad The Bad - Healthcare costs overall reduced. - Bring the research to them/promote economic growth. The Good The Good - Ethically, this tech lacks globally-accepted framework of control/regulation. - Conflicting views on restrictions. Varying restrictions government to government/institution to institution. - CEB has input: need for universal agenda. - At this stage moral complexity of tech is low. Difficult choices are down the road. Ethical Implications Ethical Implications Two major concerns: 1) "Too much potential harm. We should be denouncing this technology instead!" 2) "This is not what we do at UNFPA. We should be focusing on improving our approach to our mandate, not on things that have nothing to do with us." Causes For Concern Causes for Concern Questions? Questions?

Biotech Presentation for Stocks

Transcript: Stock Performance We first started out buying stocks from Cellgene Corp.(6 shares) and Prana Biotechnology Limited (16 shares). Though we decided to change the Cellgene Corporation company because we lost profit in our investment (after the first five weeks). Our total amount of money was $990.84 after the Cellgene and Prana investments. We lost $17.16 in the Cellgene investment, whereas in our Prana investment we gained $7.98 dollars. If we cumulatively add these result we have lost $9.18 cents in total. Therefore, we have decided upon changing the Cellgene investment to a different company in hopes of attaining more revenue. Our choice for future investments is Gentium S.p.A (GENT). It is a biopharmaceutical company focused on the development defibrotide, an investigational drug based on single stranded and double stranded DNA. It is focused on finding critical trials for hepatic veno-occlusive disease (VOD). We bought 5 shares for GENT and 160 shares for PRANA in hopes of gaining $500 dollars or more. But we saw GENT losing a lot of money, so we removed that company and focused our stocks solely on Prana, 175 stocks. Prana was rising due to the fact that a news story mentioned the investigation PBT2 for Alzheimer Treatment. Why Did we Buy Stocks in the first place? "About Us." About Celgene Corporation A Biopharmaceutical Company. N.p., n.d. Web. 18 Dec. 2013. <http://www.celgene.com/about-celgene/biopharmaceutical-company-home.aspx> " Company Profile." – Gentium SpA. N.p., n.d. Web. 18 Dec. 2013. <http://www.gentium.com/about-us/company-profile> "Gentium S.p.A.." News. N.p., 18 Dec. 2013. Web. 18 Dec. 2013. <http://topics.nytimes.com/top/news/business/companies/gentium-spa/>. "Prana Drug Treatment PBT2 Named One of Top Neuroscience Projects to Watch." Yahoo Finance. N.p., n.d. Web. 18 Dec. 2013. <http://finance.yahoo.com/news/prana-drug-treatment-pbt2-named-130000578.html> WORKS Cited Stock performance Graphs Our Company Descriptions PRAN Symbol Prana Biotechnology Limited (ADR) Reason for Purchasing: Their stock value is in the green zone. They are developing a new drug called PBT2, which aids in neurological diseases. This medication can further help aid people with Huntington Disease and Alzheimer disease. We purchased stocks because we wanted to practice in a safe environment. Investing with stocks is a real risk and we bought stock to practice. By Alan and Will Our Final Value of our Stock Discussion At the end Prana ended up gaining the most profit of all the companies invested. In the last week, we earned a profit value of $267.40. But if we subtract the amount we initially lost, $9.16, in reality we earned $258.24. The Main Reason why we changed companies was because we calculated that we were losing money from our other companies, and only Prana was making a profit. We wanted to test the waters and make a bold decision before our investment would go down the drain. Gentium S.p.A. (GENT - NASDAQ) is a bio pharmaceutical company, headquartered in Villa Guardia (Como) - Italy, focused on development and manufacture of active ingredients derived from natural sources as potential therapeutic agents.Defibrotide, a drug based on single-stranded DNA extracted from pig intestines, is Gentium’s most advanced product candidate. Defibrotide has been granted “orphan” status by the Food and Drug Administration (FDA) and Orphan Medicinal Product Designation by the European Medicines Agency (EMA) both to treat and to prevent hepatic hepatic veno-occlusive disease (VOD), a condition in which some of the veins in the liver are blocked as a result of cancer treatments Stock Symbol: CELG Cellgene Corporation Reason for Purchasing: Develops therapies for cancer and other inflammatory disorders .At Celgene, they deliver truly innovative and life-changing drugs for their patients. There mission as a company is to build a major global bio pharmaceutical corporation while focusing on the discovery, the development, and the commercialization of products for the treatment of cancer and other severe, immune, inflammatory conditions.There are more than 300 clinical trials at major medical centers using compounds from Celgene. Investigational compounds are being studied for patients with incurable hematological and solid tumor cancers, including multiple myeloma, myelodysplastic syndromes, chronic lymphocyte leukemia (CLL), non-Hodgkin's lymphoma (NHL), myelofibrosis, small cell lung cancer and prostate cancer.

Now you can make any subject more engaging and memorable